FIRE-9 trial: chemo after colon cancer metastasis removal
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether giving chemotherapy after surgery or ablation (destroying spots of cancer) can improve outcomes in people with metastatic colon or rectal cancer. It compares post-treatment chemotherapy strategies to reduce the chance the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) and can sign informed consent.
- Your colon or rectal cancer has been proven by a biopsy/pathology test.
- Your metastatic tumors have been fully removed or effectively treated, typically within 3–10 weeks before the trial starts, and the first tumor has also been removed if present.
- Your scans must show no remaining active metastatic cancer at the start (CT and/or MRI within 10 weeks).
- Your overall health is good enough for treatment (ECOG performance status 0–2).
- Your blood tests, liver/kidney function, and heart condition meet the trial limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
This Phase 3 trial compares two chemotherapy regimens after surgery in people whose MRD test is positive, meaning tiny remaining cancer cells may still be present. It aims to see which treatment helps prevent cancer coming back more effectively.
This trial tests whether giving chemotherapy before surgery can improve outcomes for people with colon cancer that has grown into nearby tissue or lymph nodes but hasn't spread to other organs. It is for patients whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
This trial tests a stronger chemo combination (FOLFOXIRI) versus the standard ones (CAPOX or FOLFOX), both followed by chemoradiation, then surgery or a watch-and-wait approach for people with high-risk locally advanced rectal cancer. The goal is to see which approach works better at preventing the cancer from coming back.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.